Intuitive Surgical Inc. (ISRG) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

ISRG scores 75 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 15%; FCF yield 1.66%), Whale 13F Flow at 15/20 (institutional accumulation and options positioning), Insider Conviction at 12/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 14/20 (beta 0.97; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 26; Piotroski F 9/9; Debt/Equity 0.06). The strongest pillar is the forensic balance sheet, which indicates low financial-distress risk per the metrics supplied. The weakest pillar is insider conviction, which signals less insider-side confirmation than the other pillars. Valuation is the central tradeoff: per the market data, the stock trades at a trailing P/E of 54.5, a forward P/E of 45.8, and an EV/EBITDA of 46, while the FCF yield is 1.66%. A prospective investor would be weighing a high-quality, low-leverage business against a premium price where near-term cash yield is thin, so returns would depend heavily on sustained growth rather than current cash distributions. This is an educational reading of the rating, not personalized advice.

Intuitive Surgical Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Industrial Specialties. The source data references a da Vinci robotic systems franchise, with procedures (including general surgery, thoracic, and bariatric categories) performed using these systems. —

Revenue rose from $7.12B (FY 2023) to $10.06B (FY 2025), and net income from $1.80B to $2.86B over the same span. Per the market data, operating margin is 29.3%, net margin 28.4%, and gross margin 66%, with ROIC at 15%. The Altman Z-Score is 26 and the Piotroski F-Score is 9/9, both 's forensic pillar, and Debt/Equity is 0.06. The FY 2023 debt figure ($20.02B) is reported as provided in the source and is inconsistent in scale with the FY 2024 and FY 2025 figures; this discrepancy is not resolved in the source data.

• 🐂 Primary Bull Case: Forensic balance sheet scores 18/20 with Altman Z 26, Piotroski F 9/9, and Debt/Equity 0.06, alongside FY 2025 revenue of $10.06B and FCF of $2.58B. With Fundamental Cash Engine at 16/20 (ROIC 15.0%, FCF yield 1.66%) and Institutional Whale Flow at 12/20, sustained execution supports upside toward the top of the $328.57 – $603.88 52-week range.
• 🐻 Primary Bear Case: Trailing P/E of 54.5 and forward P/E of 45.8 against an FCF yield of 1.66%, with a disclosed GLP-1 bariatric procedure headwind. Investors must weigh 54.5x trailing P/E and 46.0x EV/EBITDA against 29.3% operating margins and a 0.97 macro beta if sector demand softens.

The supply_chain field is NONE and the sector/industry is Health Care / Industrial Specialties. The one documented link runs from NVO (Novo Nordisk, the GLP-1 drug source) to ISRG, typed POTENTIAL_LOSER with a CONFIRMED_FILING evidence tier. The mechanism is 2nd-order demand: GLP-1 weight-loss treatment reduces the bariatric surgery pipeline feeding da Vinci procedures. The source states bariatrics is under 5% of total global da Vinci procedures, limiting the magnitude. The competing explanation is that patients who plateau or lose coverage on GLP-1 therapy may re-enter the robotic bariatric funnel 12–24 months later. Watch item: the next catalyst named is Intuitive's quarterly worldwide procedure growth and bariatric sub-trend commentary.

• Key Question #1: What is the FY 2023 debt figure of $20.02B, given it is far out of scale with FY 2024 ($996.1M) and FY 2025 ($1.13B)?
• Key Question #2: Why is EPS reported as N/A across all three periods when trailing EPS is given as $8.24?
• Key Question #3: What is the FY 2023 cash balance, which is reported as N/A?